Neurogene (NGNE) Return on Sales (2018 - 2025)

Neurogene's Return on Sales history runs 5 years deep, the most recent figure standing at 1.21% for Q2 2025.

• Quarterly Return on Sales fell 86.0% year-over-year to 1.21% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 1.21% (down 3.0% YoY) and the FY2024 annual result came in at 2.04%, changed N/A from the prior year.
• Return on Sales was 1.21% for Q2 2025 at Neurogene, up from 1.55% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q4 2023 and bottomed at 1.55% in Q4 2024.
• A 3-year average of 0.65% and a median of 0.34% in 2024 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 34 bps in 2024, while the deepest fall reached 155 bps in 2024.
• Neurogene's Return on Sales stood at 0.0% in 2023, then tumbled by 294944 bps to 1.55% in 2024, then gained by 22 bps to 1.21% in 2025.
• Business Quant data shows NGNE's Return on Sales at 1.21% in Q2 2025, 1.55% in Q4 2024, and 1.45% in Q3 2024.